Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 2/20 | 0.33 |
| ▸ | TK1 | P04183 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837510 | 1.00 | POLB (0.44) | POLBABL1RIN1P2RY6P2RY2 | |
| SCHEMBL12579728 | 0.95 | POLB (0.46) | POLBABL1RIN1P2RY6P2RY2 | |
| SCHEMBL837611 | 0.95 | POLB (0.46) | POLBABL1RIN1P2RY6P2RY2 | |
| SCHEMBL836118 | 0.95 | POLB (0.46) | POLBABL1RIN1P2RY6P2RY2 | |
| SCHEMBL10095190 | 0.86 | POLB (0.43) | POLBABL1RIN1P2RY6P2RY2 | |
| SCHEMBL837720 | 0.86 | POLB (0.43) | POLBABL1RIN1P2RY6P2RY2 | |
| SCHEMBL10095196 | 0.85 | POLB (0.39) | POLBABL1RIN1P2RY6P2RY2 | |
| SCHEMBL837389 | 0.80 | POLB (0.40) | POLBABL1RIN1P2RY6P2RY2 | |
| SCHEMBL12197787 | 0.80 | POLB (0.40) | POLBABL1RIN1P2RY6P2RY2 | |
| SCHEMBL836805 | 0.80 | POLB (0.37) | POLBABL1RIN1P2RY6P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143396-B2 | 1-[2′, 3′ -dideoxy-3′ C- (hydroxymethyl)—beta-D-erythro-pentofuranosyl] cytosine derivatives as HIV inhibitors | MEDIVIR AB (SE) | 2012-03-27 | — | — | US | disclosed |
| EP-1899352-B1 | 1- [2' , 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | MEDIVIR AB (SE) | 2011-10-05 | — | — | EP | disclosed |
| EP-2336135-A2 | 1-[2',3'-dideoxy-3'c-(hydroxymethyl)- beta-d-erythro-pentofuranosyl]cytosine derivatives as HIV inhibitors | Medivir AB (SE) | 2011-06-22 | — | — | EP | disclosed |
| US-20110112294-A1 | 1-[2', 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7888367-B2 | reverse transcriptase mutants which allow an obligate chain terminating nucleoside- or nucleotide phosphate to be excised from the nascent DNA strand by ATP- or pyrophosphate-mediated excision | MEDIVIR AB (SE) | 2011-02-15 | — | — | US | disclosed |
| US-7888367-B2 | reverse transcriptase mutants which allow an obligate chain terminating nucleoside- or nucleotide phosphate to be excised from the nascent DNA strand by ATP- or pyrophosphate-mediated excision | MEDIVIR AB (SE) | 2011-02-15 | — | — | US | disclosed |
| US-20080221140-A1 | 1-[2',3' -Dideoxy-3' C-(Hydroxymethyl) - Beta-D-Erythro-Pentofuranosyl] Cytosine Derivatives as Hiv | MEDIVIR AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221140-A1 | 1-[2',3' -Dideoxy-3' C-(Hydroxymethyl) - Beta-D-Erythro-Pentofuranosyl] Cytosine Derivatives as Hiv | MEDIVIR AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2007006707-A1 | 1- [2' , 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112294-A1 | 1-[2', 3' -DIDEOXY-3' C- (HYDROXYMETHYL) - BETA-D-ERYTHRO-PENTOFURANOSYL] CYTOSINE DERIVATIVES AS HIV INHIBITORS | NUDT1, RRM2, TYMP | POLB 16/4885ABL1 4053/4885RIN1 779/4885 |
| US-20080221140-A1 | 1-[2',3' -Dideoxy-3' C-(Hydroxymethyl) - Beta-D-Erythro-Pentofuranosyl] Cytosine Derivatives as Hiv | NUDT1, TYMP, DPYD | POLB 14/4885ABL1 3856/4885RIN1 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.